Developed by Ionis Pharmaceuticals, Dawnzera is the first RNA-targeted medicine approved for HAE, designed to target plasma ...

The biosimilar will be available to any licensed specialty pharmacy in the United States at a 95% discount from Stelara, starting January 1, 2026.

Large language models (LLMs) were more likely to suggest inferior treatment options when reviewing hypothetical cases when ...

National registry study finds overall survival improved across the board after the introduction of immune checkpoint ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

This recent study underscores the fact that biomarkers serve not merely as statistical instruments but as insights into ...

A new study finds Medicare beneficiaries are facing higher deductibles and cost-sharing requirements following changes ...

Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ...

GLP-1 receptor agonists show promise in treating hidradenitis suppurativa, offering significant symptom relief and improved ...

Prefilled syringes of Imuldosa now have the lowest wholesaler acquisition cost among all branded ustekinumab biosimilars, ...

Tonmya is the first new fibromyalgia treatment approved by the FDA in more than 15 years, providing symptom relief for at ...

New study results provide insight into improving heart health through behavior changes, such as taking standing breaks ...